BioSpace News Archive

Windtree Therapeutics, Inc. today announced that on Tuesday, October 19, 2021 at 8:00 am Eastern Time it will host a Key Opinion Leader (KOL) webinar on istaroxime for the treatment of acute heart failure and the upcoming data in early cardiogenic shock.

Plus Therapeutics, Inc. announced that the Company will report third quarter 2021 financial results on Thursday, October 21, 2021, after market close.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for REGEN-COV

Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference being held on October 14, 2021.

Recognizes achievements in AI-enabled drug discovery Highlights how Evaxion’s platforms help to design novel immunotherapies efficiently

Lupin Pharmaceuticals Inc. is voluntarily recalling the below-mentioned batches of Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets to the consumer level.

HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries.

Longeveron Inc. announced today that Geoff Green, Chief Executive Officer of Longeveron, will present at the Dawson James Small Cap Growth Conference on Thursday, October 21, 2021 at 11:25 a.m. ET in Jupiter, Florida.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), today announced the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety (AjDA).

Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market.